{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:53:10Z","timestamp":1767963190006,"version":"3.49.0"},"reference-count":42,"publisher":"Impact Journals, LLC","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,6,14]]},"DOI":"10.18632\/oncotarget.9652","type":"journal-article","created":{"date-parts":[[2016,5,29]],"date-time":"2016-05-29T14:02:16Z","timestamp":1464530536000},"page":"35552-35561","source":"Crossref","is-referenced-by-count":20,"title":["Sub-acute systemic erythropoietin administration reduces ischemic brain injury in an age-dependent manner"],"prefix":"10.18632","volume":"7","author":[{"given":"Peter","family":"Th\u00e9riault","sequence":"first","affiliation":[{"name":"Neuroscience Laboratory, CHU de Qu\u00e9bec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, Qu\u00e9bec City, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Le B\u00e9hot","sequence":"additional","affiliation":[{"name":"Neuroscience Laboratory, CHU de Qu\u00e9bec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, Qu\u00e9bec City, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"ElAli","sequence":"additional","affiliation":[{"name":"Neuroscience Laboratory, CHU de Qu\u00e9bec Research Center and Department of Psychiatry and Neuroscience, Faculty of Medicine, Laval University, Qu\u00e9bec City, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Rivest","sequence":"additional","affiliation":[{"name":"Neuroscience Laboratory, CHU de Qu\u00e9bec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, Qu\u00e9bec City, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,5,29]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1161\/CIRCULATIONAHA.109.192666","article-title":"Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association","volume":"121","author":"Haase","year":"2010","journal-title":"Circulation"},{"key":"2","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1161\/STROKEAHA.107.505776","article-title":"Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier","volume":"39","author":"Pandey","year":"2008","journal-title":"Stroke"},{"key":"3","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/nm782","article-title":"Real-timeimaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse","volume":"8","author":"Furie","year":"2002","journal-title":"Nat. Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1093\/brain\/awp162","article-title":"Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact","volume":"132","author":"Yepes","year":"2009","journal-title":"Brain"},{"key":"5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/272549a0","article-title":"Molecular mechanism of physiological fibrinolysis","volume":"272","author":"Collen","year":"1978","journal-title":"Nature"},{"key":"6","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1471-4159.2007.04866.x","article-title":"Neuroprotection and stroke: time for a compromise","volume":"103","author":"Vivien","year":"2007","journal-title":"J. Neurochem"},{"key":"7","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/jcbfm.2011.127","article-title":"Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence","volume":"31","author":"Touz\u00e9","year":"2011","journal-title":"J. Cereb. Blood Flow Metab"},{"key":"8","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","author":"The National Institute of Neurological Disorders (NIND) and Stroke rt-PA Stroke Study Group","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"9","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.79.4.920","article-title":"Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis","volume":"79","author":"Collen","year":"1989","journal-title":"Circulation"},{"key":"10","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1212\/01.wnl.0000244492.99737.a8","article-title":"Prediction of thrombolytic efficacy in acute ischemic stroke using thin-section noncontrast CT","volume":"67","author":"Kim","year":"2006","journal-title":"Neurology"},{"key":"11","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke","volume":"359","author":"Wahlgren","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"12","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(10)60491-6","article-title":"Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials","volume":"375","author":"Davis","year":"2010","journal-title":"Lancet"},{"key":"13","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1161\/01.STR.0000165902.18021.5b","article-title":"Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry","volume":"36","author":"Weiss","year":"2005","journal-title":"Stroke"},{"key":"14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1152\/physrev.1992.72.2.449","article-title":"Erythropoietin: structure, control of production, and function","volume":"72","author":"Jelkmann","year":"1992","journal-title":"Physiol. Rev"},{"key":"15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.20131189","article-title":"Erythropoietin guides multipotent hematopoietic progenitor cells toward an erythroid fate","volume":"211","author":"Nerlov","year":"2014","journal-title":"J. Exp. Med."},{"key":"16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/sj.ki.5001546","article-title":"Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise","volume":"70","author":"Cerami","year":"2006","journal-title":"Kidney Int"},{"key":"17","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/brain\/awh703","article-title":"Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin","volume":"129","author":"Frahm","year":"2006","journal-title":"Brain"},{"key":"18","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/01.STR.0000132196.49028.a4","article-title":"Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats","volume":"35","author":"Chopp","year":"2004","journal-title":"Stroke"},{"key":"19","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/00004647-199906000-00007","article-title":"A potential role for erythropoietin in focal permanent cerebral ischemia in mice","volume":"19","author":"Petit","year":"1999","journal-title":"J. Cereb. Blood Flow Metab"},{"key":"20","first-page":"415","article-title":"The neurovascular unit and combination treatment strategies for stroke. Trends Pharmacol","volume":"33","author":"Chopp","year":"2012","journal-title":"Sci"},{"key":"21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.1098313","article-title":"Derivatives of erythropoietin that are tissue protective but not erythropoietic","volume":"305","author":"Villa","year":"2004","journal-title":"Science"},{"key":"22","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1161\/STROKEAHA.107.483008","article-title":"Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia\/ischemia in rats","volume":"38","author":"Chen","year":"2007","journal-title":"Stroke"},{"key":"23","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2174\/0929867322666150114152134","article-title":"Erythropoietin in stroke therapy: friend or foe","volume":"22","author":"Tang","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0006-8993(01)03270-X","article-title":"Aging has a complex effect on a rat model of ischemic stroke","volume":"925","author":"Kadar","year":"2002","journal-title":"Brain Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/sj.jcbfm.9600417","article-title":"Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice","volume":"27","author":"Wei","year":"2007","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"26","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3109\/00207454.2014.966354","article-title":"Intra-artery infusion of recombinant human erythropoietin reduces blood-brain barrier disruption in rats following cerebral ischemia and reperfusion","volume":"125","author":"Zhao","year":"2015","journal-title":"Int. J. Neurosci."},{"key":"27","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood-2013-12-543074","article-title":"GpIb\u03b1-VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice","volume":"123","author":"De Lizarrondo","year":"2014","journal-title":"Blood"},{"key":"28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1074-7613(03)00174-2","article-title":"Blood monocytes consist of two principal subsets with distinct migratory properties","volume":"19","author":"Littman","year":"2003","journal-title":"Immunity"},{"key":"29","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jmcb\/mjt028","article-title":"A deficiency in CCR2+ monocytes: the hidden side of Alzheimer's disease","volume":"5","author":"Rivest","year":"2013","journal-title":"J. Mol. Cell Biol."},{"key":"30","doi-asserted-by":"crossref","first-page":"H365","DOI":"10.1152\/ajpheart.00562.2015","article-title":"Aging is associated with changes to the biomechanical properties of the posterior cerebral artery and parenchymal arterioles","volume":"310","author":"Dorrance","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"31","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1046\/j.1365-2990.2000.00265.x","article-title":"Oedema and glial cell involvement in the aged mouse brain after permanent focal ischaemia","volume":"26","author":"Davies","year":"2000","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"32","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/bs.apha.2014.07.001","article-title":"Aging, the metabolic syndrome, and ischemic stroke: redefining the approach for studying the blood-brain barrier in a complex neurological disease","volume":"71","author":"Huber","year":"2014","journal-title":"Adv. Pharmacol"},{"key":"33","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1084\/jem.20021067","article-title":"Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis","volume":"198","author":"Ghezzi","year":"2003","journal-title":"J. Exp. Med."},{"key":"34","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/BF03402029","article-title":"Erythropoietin therapy for acute stroke is both safe and beneficial","volume":"8","author":"R\u00fcther","year":"2002","journal-title":"Mol. Med"},{"key":"35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13054-015-0761-8","article-title":"Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: a randomized, prospective, placebo-controlled clinical trial","volume":"19","author":"Huang","year":"2015","journal-title":"Crit. Care"},{"key":"36","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/STROKEAHA.109.574418","article-title":"Combination of Tissue-Plasminogen Activator With Erythropoietin Induces Blood-Brain Barrier Permeability, Extracellular Matrix Disaggregation, and DNA Fragmentation After Focal Cerebral Ischemia in Mice","volume":"41","author":"Hermann","year":"2010","journal-title":"Stroke"},{"key":"37","first-page":"1149","article-title":"Effects of Myeloablation, Peripheral Chimerism and Whole Body Irradiation on the Entry of Bone Marrow-Derived Cells Into the Brain","volume":"21","author":"Rivest","year":"2011","journal-title":"Cell Transplant"},{"key":"38","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/jcbfm.2011.8","article-title":"Thrombotic distal middle cerebral artery occlusion produced by topical FeCl(3) application: a novel model suitable for intravital microscopy and thrombolysis studies","volume":"31","author":"Dalkara","year":"2011","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"39","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1002\/cne.23363","article-title":"Migration of bone marrow-derived cells into the central nervous system in models of neurodegeneration","volume":"521","author":"Rivest","year":"2013","journal-title":"J. Comp. Neurol."},{"key":"40","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1385\/MN:34:3:221","article-title":"Molecular and Cellular Immune Mediators of Neuroprotection","volume":"34","author":"Rivest","year":"2006","journal-title":"Mol. Neurobiol"},{"key":"41","first-page":"1297","article-title":"Tissue-Plasminogen Activator Attenuates Alzheimer's Disease-Related Pathology Development in APPswe\/PS1 Mice","volume":"41","author":"Rivest","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"42","first-page":"1078","article-title":"Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease","volume":"132","author":"Rivest","year":"2009","journal-title":"Brain"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T06:21:34Z","timestamp":1718605294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,29]]},"references-count":42,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2016,6,14]]}},"alternative-id":["9652","27248662"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.9652","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,29]]}}}